Adding cognitive-behavioral therapy to pharmacotherapy for panic disorder: Issues and strategies

CNS Spectrums

Volumn 10, Issue 9 SUPPL. 12, 2005, Pages 32-39

  Otto, Michael W ^a   Powers, Mark ^a   Smits, Jasper A J ^b  

^a BOSTON UNIVERSITY   (United States)

^b SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL PROTOCOL; COGNITIVE THERAPY; EVIDENCE BASED MEDICINE; FEAR; HUMAN; PANIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SAFETY; TREATMENT OUTCOME;

EID: 27444444114     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900026523     Document Type: Review

References (65)

1. Otto MW, Pollack MH, Maki KM. Empirically supported treatments for panic disorder: costs, benefits, and stepped care. J Consult Clin Psychol. 2000;68:556-563,
2. Margraf J, Barlow DH, Clark DM, Telch MJ. Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up. Behav Res Ther. 1993;31:1-8.
3. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164:759-69.
4. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev. 1995;15:819-844.
5. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000;283:2529-2536.
6. Hofmann SG, Barlow DH, Papp LA, et al. Pretreatment attrition in a comparative treatment outcome study on panic disorder. Am J Psychiatry. 1998;155:43-47.
7. Craske MG, Brown TA, Barlow DH. Behavioral treatment of panic: a two year follow-up. Behav Ther. 1991;22:289-304.
8. Tsao JC, Lewin MR, Craske MG. Effects of cognitive-behavior therapy for panic disorder on comorbid conditions: replication and extension. Behav Ther. 2002;33:493-509.
9. Telch MJ, Schmidt NB, Jaimez TL, Jacquin KM, Harrington PJ. Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol. 1995;63:823-830.
10. Telch MJ, Lucas RA. Combined pharmacological and psychological treatment of panic disorder; current status and future directions. In: Wolfe BE, Maser JD, eds. Treatment of Panic Disorder. Washington DC: American Psychiatric Association Press; 1994:177-197.
11. Schmidt NB, Wollaway-Bickel K, Trakowski JH, Santiago HT, Vasey M. Antidepressant discontinuation in the context of cognitive behavioral treatment for panic disorder. Behav Res Ther. 2002;40:67-73.
12. Mavissakalian M. Sequential combination of imipramine and self-directed exposure in the treatment of panic disorder with agoraphobia. J Clin Psychiatry. 1990;51:184-188.
13. Marks IM, Swinson RP, Basoglu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry. 1993;162:776-787.
14. Whittal ML, Otto MW, Hong JJ. Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. Behav Res Ther. 2001;39:939-945.
15. Otto MW, Hong JJ, Safren SA. Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy. Curr Pharm Des. 2002;8:75-80.
16. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994;55:200-205.
17. Otto MW, Pollack MH, Penava SJ, Zucker BG. Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series. Behav Res Ther. 1999;37:763-770.
18. Heldt E, Manfro GG, Kipper L, et al. Treating medication-resistant panic disorder: predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom. 2003;72:43-48.
19. Heldt E, Manfro GG, Kipper L, Blaya C, Isolan L, Otto MW. One-year follow-up of pharmacotherapy-resistant patients with panic disorder treated with cognitive-behavior therapy: outcome and predictors of remission. Behav Res Ther. In press.
20. Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000;20:556-559.
21. Khaldi S, Kornreich C, Dan B, Pelc I. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol. 2003;23:100-101.
22. Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155;992-3.
23. Addis ME, Hatgis C, Krasnow AD, Jacob K, Bourne L, Mansfield A. Effectiveness of cognitive-behavioral treatment for panic disorder versus treatment as usual in a managed care setting. J Consult Clin Psychol. 2004;72:625-635.
24. Stuart GL, Treat TA, Wade WA. Effectiveness of an empirically based treatment for panic disorder delivered in a service clinic setting: 1-year follow-up. J Consult Clin Psychol. 2000;68:506-512.
25. Wade WA, Treat TA, Stuart GL. Transporting an empirically supported treatment for panic disorder to a service clinic setting: a benchmarking strategy. J Consult Clin Psychol. 1998;66:231-239.
26. Goisman RM, Warshaw MG, Keller MB. Psychosocial treatment prescriptions for generalized anxiety disorder, panic disorder, and social phobia, 1991-1996. Am J Psychiatry. 1999;156:1819-21.
27. Stein MB, Sherbourne CD, Craske MG, et al. Quality of care for primary care patients with anxiety disorders. Am J Psychiatry. 2004;161:2230-2237.
28. Addis ME. Methods for disseminating research products and increasing evidence-based practice: promises, obstacles, and future directions. Clin Psychol Sci Pract. 2002;9:367-378.
29. Gotham HJ. Diffusion of mental health and substance abuse treatments: development, dissemination, and implementation. Clin Psychol Sci Pract. 2004;11:160-176.
30. Stirman SW, Chrits-Shristoph P, DeRubeis RJ. Achieving successful dissemination of empirically supported psychotherapies: a synthesis of dissemination theory. Clin Psychol Sci Pract. 2004;11:343-359.
31. Craske MG, Barlow DH, Meadows EA. Mastery of Your Anxiety and Panic: Therapist Guide for Anxiety, Panic, and Agoraphobia. 3rd ed. Oxford: Oxford University Press (Graywind Publications); 2000.
32. Zinbarg RE, Craske MG, Barlow DH. Mastery of Your Anxiety and Worry: Therapists Guide (Treatments That Work). Oxford: Oxford University Press (Graywind Publications); 1993.
33. Barlow DA, Allen LB, Choate ML. Toward a unified treatment for emotional disorders. Behav Ther. 2004;35:205-230.
34. Otto MW, Jones JC, Barlow DH, Craske MG. Stopping Anxiety Medication (SAM): Panic Control Therapy for Benzodiazepine Discontinuation. San Antonio, Texas: Oxford University Press; 1996.
35. Salkovskis PM, Clark DM, Hackmann A. Treatment of panic attacks using cognitive therapy without exposure or breathing retraining. Behav Res Ther. 1991;29:161-166.
36. Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry. 1992;149:778-783.
37. Clark DM, Salkovskis PM, Hackmann A, Wells A, Ludgate J, Gelder M. Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999;67:583-589.
38. Craske MG, Maidenberg E, Bystritsky A. Brief cognitive-behavioral versus nondirective therapy for panic disorder. J Behav Ther Exp Psychiatry. 1995;26:113-120.
39. Hecker JE, Losee MC, Roberson-Nay R, Maki K. Mastery of Your Anxiety and Panic and brief therapist contact in the treatment of panic disorder. J Anxiety Disord. 2004;18:111-126.
40. Otto MW, Smits JA, Reese HE. Cognitive-behavioral therapy for the treatment of anxiety disorders. J Clin Psychiatry. 2004;65(suppl 5):34-41.
41. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24:461-470.
42. McNally RJ. Psychological approaches to panic disorder: a review. Psychol Bull. 1990;108:403-419.
43. Barlow DH. Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic. New York, NY: The Guilford Press; 1988.
44. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001;108:4-32.
45. Salkovskis PM, Clark DM, Gelder MG. Cognition-behaviour links in the persistence of panic. Behav Res Ther. 1996;34:453-458.
46. Manfro GG, Otto MW, McArdle ET, Worthington JJ3, Rosenbaum JF, Pollack MH. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord. 1996;41:135-139.
47. Jang KL, Stein MB, Taylor S, Livesley WJ. Gender differences in the etiology of anxiety sensitivity: a twin study. J Gend Specif Med. 1999;2:39-44.
48. Peterson RA, Reiss S. Anxiety Sensitivity Index Manual. Worthington, Ohio: IDS; 1987.
49. McNally RJ. Anxiety sensitivity and panic disorder. Biol Psychiatry. 2002;52:938-946.
50. Gardenswartz CA, Craske ME. Prevention of panic disorder. Behav Ther. 2001;32:725-737.
51. Park JM, Mataix-Cols D, Marks IM, et al. Two-year follow-up after a randomised controlled trial of self- and clinician-accompanied exposure for phobia/panic disorders. Br J Psychiatry. 2001;178:543-548.
52. Sutherland SM, Davidson JRT. B-blockers and benzodiazepines in pharmacotherapy. In: Stein MB, ed. Social Phobia: Clinical and Research Perspectives. Washington DC: American Psychiatric Press; 1995:323-6.
53. Powers MB, Smits J, Leyro TM, Otto M. Translation Research Perspectives on Maximizing the Effectiveness of Exposure Therapy. Academic Press; 2005. In press.
54. Bouton ME. Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry. 2002;52:976-986.
55. Otto MW, Smits JAJ, Reese HE. Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clin Psychol Sci Pract. 2005;12:72-86.
56. Bouton ME, Kenney FA, Rosengard C. State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci. 1990;104:44-55.
57. Craske MG, Lang AJ, Aikens D, Mystowski JL. Cognitive behavioral therapy for nocturnal panic. Behav Ther. 2005;36:43-54.
58. Broman-Fulks JJ, Berman ME, Rabian BA, Webster MJ. Effects of aerobic exercise on anxiety sensitivity. Behav Res Ther. 2004;42:125-136.
59. Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry. 1998;155:603-609.
60. Ito LM, de Araujo LA, Tess VL, Barros-Neto TP, Asbahr FR, Marks I. Self-exposure therapy for panic disorder with agoraphobia: randomised controlled study of external v. interoceptive self-exposure. Br J Psychiatry. 2001;178:331-336.
61. Otto MW, Pollack MH, Barlow DH. Stopping Anxiety Medication: Client Workbook. Oxford University Press (Graywind Publications); 1996.
62. Salkovskis PM, Clark DM, Hackmann A, Wells A, Gelder MG. An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia. Behav Res Ther. 1999;37:559-574.
63. Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL. A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol. 1994;62:865-869.
64. Association for Advancement of Behavior Therapy. Available at: http://www. aabt.org. Accessed August 2005.
65. Anxiety Disorders Association of America. Available at: http://www.adaa.org. Accessed August 2005.